Celldex Therapeutics, Inc.

General ticker "CLDX" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $1.9B (TTM average)

Celldex Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -8.2%.

Estimated limits based on current volatility of 2.1%: low 20.30$, high 21.16$

Factors to consider:

  • Earnings expected soon, date: 2025-05-05 bmo
  • Price in estimated range

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

  • 2024-12-31 to 2025-12-31 estimated range: [8.79$, 23.99$]
  • 2025-12-31 to 2026-12-31 estimated range: [4.63$, 13.42$]

Financial Metrics affecting the CLDX estimates:

  • Negative: Non-GAAP EPS, $ of -2.45 <= 0.04
  • Negative: Operating cash flow per share per price, % of -8.56 <= 1.79
  • Negative: negative Net income
  • Positive: Interest expense per share, $ of 0 <= 0
  • Positive: Inventory ratio change, % of 0 <= 0
  • Negative: negative Operating income
  • Positive: Shareholder equity ratio, % of 94.28 > 63.75
  • Positive: Industry inventory ratio change (median), % of 0 <= 0

Similar symbols

Short-term CLDX quotes

2025-03-212025-03-242025-03-252025-03-262025-03-272025-03-282025-03-312025-04-012025-04-022025-04-032025-04-042025-04-072025-04-082025-04-092025-04-102025-04-112025-04-142025-04-152025-04-162025-04-172025-04-212025-04-222025-04-232025-04-242025-04-252025-04-282025-04-292025-04-302025-05-012025-05-0215161718192021
Price $

Long-term CLDX plot with estimates

1020304050Jul 2023Jan 2024Jul 2024Jan 2025Jul 2025Jan 2026Jul 2026Jan 2027−0.8−0.6−0.4−0.20
CLDXS&P500Health CareNon-GAAP EPS EstimateNon-GAAP EPS ActualPrice $Non-GAAP EPS $

Financial data

YTD 2022-12-31 2023-12-31 2024-12-31
Operating Revenue $2.36MM $6.88MM $7.02MM
Operating Expenses $117.59MM $161.43MM $202.10MM
Operating Income $-115.23MM $-154.54MM $-195.08MM
Non-Operating Income $2.91MM $13.11MM $37.22MM
R&D Expense $82.26MM $118.01MM $0.01MM
Income(Loss) $-112.33MM $-141.43MM $-157.86MM
Profit(Loss)* $-122.78MM $-141.43MM $-157.86MM
Stockholders Equity $326.20MM $429.17MM $747.00MM
Assets $352.74MM $465.63MM $792.34MM
Operating Cash Flow $-103.73MM $-107.29MM $-157.78MM
Capital expenditure $1.83MM $1.82MM $0.00MM
Investing Cash Flow $89.94MM $-105.78MM $-290.13MM
Financing Cash Flow $4.08MM $218.46MM $441.45MM
Earnings Per Share** $-2.62 $-2.92 $-2.45

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.